Korro Bio (KRRO)

Executive Summary

Korro Bio is a publicly traded genetic medicines company pioneering a novel class of RNA editing therapies based on its proprietary OPERA® platform. The platform enables precise, single-base editing of RNA, offering tunable and reversible modulation of protein expression with a favorable safety profile. Korro is initially focused on liver and central nervous system disorders, leveraging the platform's ability to correct disease-causing mutations at the RNA level without permanent genomic alterations. The company’s lead program, KRRO-121, targets hyperammonemia in urea cycle disorders and hepatic encephalopathy, while KRRO-110 is in Phase 1/2 development for Alpha-1 Antitrypsin Deficiency (AATD). With a market capitalization of approximately $170 million, Korro represents an early-stage investment opportunity in the rapidly evolving RNA editing space. Korro’s pipeline is advancing with key milestones anticipated over the next 12 months. The ongoing KRRO-110 Phase 1/2 trial (NCT06677307) is actively recruiting, and interim safety and efficacy data are expected in late 2026. Additionally, the company is preparing to file an Investigational New Drug (IND) application for KRRO-121, with potential initiation of clinical trials in 2027. Korro’s platform also holds promise for CNS indications, though preclinical programs remain earlier stage. The company’s ability to demonstrate clinical proof-of-concept and differentiate from competitors like Wave Life Sciences and Ascidian Therapeutics will be critical for value creation.

Upcoming Catalysts (preview)

• Q4 2026KRRO-110 Phase 1/2 interim data readout40% success
• Q3 2026KRRO-121 IND submission70% success
• Q2 2027Preclinical proof-of-concept data for CNS program50% success